Inovio Pharmaceuticals (INO)
(Real Time Quote from BATS)
$4.18 USD
+0.12 (2.96%)
Updated Nov 22, 2024 12:38 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INO 4.18 +0.12(2.96%)
Will INO be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for INO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INO
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates
Wave Life Sciences (WVE) Reports Q3 Loss, Lags Revenue Estimates
INO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates
Exelixis (EXEL) Soars 8.6%: Is Further Upside Left in the Stock?
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
Other News for INO
Inovio price target lowered to $15 from $33 at Oppenheimer
Inovio price target lowered by $18 at Oppenheimer, here's why
Cautious Hold Recommendation on Inovio Pharmaceuticals Amid Financial Challenges and Competitive Pressures
Inovio price target lowered to $5 from $12 at H.C. Wainwright
Inovio price target lowered by $7 at H.C. Wainwright, here's why